RGC - Regencell Bioscience Holdings Limited -  [ ]

Ticker Details
Regencell Bioscience Holdings Limited
IPO Date: July 16, 2021
Sector: Healthcare
Industry: Drug Manufacturers
Market Cap: $3.21B
Activated in VL: True
Average Daily Range
Avg Daily Range: $2.99 | 7.04%
Avg Daily Range (30 D): $1.12 | 8.16%
Avg Daily Range (90 D): $1.14 | 5.54%
Institutional Daily Volume
Avg Daily Volume: 3.67M
Avg Daily Volume (30 D): .35M
Avg Daily Volume (90 D): .2M
Trade Size
Avg Trade Size (Sh.): 1,279
Avg Trade Size (Sh.) (30 D): 90
Avg Trade Size (Sh.) (90 D): 77
Institutional Trades
Total Institutional Trades: 70
Avg Institutional Trade: $.92M
Avg Institutional Trade (30 D): $.53M
Avg Institutional Trade (90 D): $1M
Avg Institutional Trade Volume: .26M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $.8M
Avg Closing Trade (30 D): $.53M
Avg Closing Trade (90 D): $1.07M
Avg Closing Volume: 76.39K
 
News
Jun 22, 2026 @ 2:53 PM
DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Off...
Source: The Law Offices Of Frank R. Cruz
Jun 22, 2026 @ 2:57 AM
FSK DEADLINE NOTICE: ROSEN, A RANKED AND LEADING F...
Source: Rosen Law Firm
Jun 22, 2026 @ 2:37 AM
REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Enc...
Source: Rosen Law Firm
Jun 21, 2026 @ 12:09 AM
RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Remind...
Source: Faruqi & Faruqi, Llp
Jun 18, 2026 @ 9:44 PM
SRAD IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR C...
Source: Rosen Law Firm
Financials
  TTM Q4 2017 FY 2017
Basic EPS $.72 $.19 $.72
Diluted EPS $.72 $.19 $.72
Revenue $3.16B $861.6M $3.16B
Gross Profit
Net Income / Loss $112.3M $28.9M $112.3M
Operating Income / Loss $271.7M $90.7M $271.7M
Cost of Revenue
Net Cash Flow $-17.7M $39.3M $-17.7M
PE Ratio    
Splits
Jun 16, 2025 38:1